Literature DB >> 15525302

Rituximab-responsive CIDP.

C Briani, G Zara, R Zambello, L Trentin, M Rana, F Zaja.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15525302     DOI： 10.1111/j.1468-1331.2004.00911.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  16 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

Review 2.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 3.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

4.  Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases.

Authors:  Daniele Velardo; Nilo Riva; Ubaldo Del Carro; Francesca Bianchi; Giancarlo Comi; Raffaella Fazio
Journal:  J Neurol       Date:  2017-03-23       Impact factor: 4.849

Review 5.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

6.  Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Authors:  Kalliopi Pitarokoili; Min-Suk Yoon; Ilka Kröger; Anke Reinacher-Schick; Ralf Gold; Christiane Schneider-Gold
Journal:  J Neurol       Date:  2017-08-23       Impact factor: 4.849

Review 7.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 8.  Inflammatory neuropathies: an update on evaluation and treatment.

Authors:  Lisa D Hobson-Webb; Peter D Donofrio
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

9.  Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

Authors:  C Hirst; S Raasch; G Llewelyn; N Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

Review 10.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.